Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

204 Results

Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Alnylam Issues 2023 Corporate Responsibility Report
BU
Alnylam Pharmaceuticals : 2023 REPORT
PU
Transcript : Alnylam Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 02, 2024
Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
BU
Transcript : Alnylam Pharmaceuticals, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 09:10 AM
Transcript : Alnylam Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 15, 2024
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
BU
Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen's Association
AQ
Alnylam CEO Yvonne Greenstreet Named 2024 Woman of the Year by Healthcare Businesswomen’s Association
BU
Transcript : Alnylam Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-08-2024 09:45 AM
Alnylam Announces Preliminary Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
AQ
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2023 Global Net Product Revenues and Provides Additional Updates
BU
Transcript : Alnylam Pharmaceuticals, Inc. - Special Call
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Piper Sandler 35th Annual Healthcare Conference, Nov-29-2023 09:30 AM
Transcript : Alnylam Pharmaceuticals, Inc. Presents at 14th Annual Jefferies London Healthcare Conference 2023, Nov-14-2023 10:00 AM
Transcript : Alnylam Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 02, 2023
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
BU
Transcript : Alnylam Pharmaceuticals, Inc. - Special Call
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
BU
Transcript : Alnylam Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 03, 2023
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
BU
Transcript : Alnylam Pharmaceuticals, Inc. - Special Call
Roche to co-develop hypertension RNAi therapeutic
AQ
Roche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk
GL
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
BU
Transcript : Alnylam Pharmaceuticals, Inc., Q1 2023 Earnings Call, May 04, 2023
Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity
BU
Alnylam Issues 2022 Corporate Responsibility Report
BU
Transcript : Alnylam Pharmaceuticals, Inc. - Special Call
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
BU
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
GL
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
AQ
PACIRA BIOSCIENCES, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure (form 8-K)
AQ
Pacira BioSciences Announces Yvonne Greenstreet to Retire from Board of Directors
GL
Pacira BioSciences Announces Yvonne Greenstreet to Retire from Board of Directors
AQ
Pacira Biosciences Announces Yvonne Greenstreet to Retire from Board of Directors
CI
Alnylam Announces Appointment of Peter Kellogg to Board of Directors
BU
Transcript : Alnylam Pharmaceuticals, Inc., Q4 2022 Earnings Call, Feb 23, 2023
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity
BU
Transcript : Alnylam Pharmaceuticals, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-09-2023 09:45 AM
Alnylam Announces Preliminary Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates
AQ
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates
BU
Alnylam Announces Updates to its Board of Directors
BU
Transcript : Alnylam Pharmaceuticals, Inc. - Special Call
Alnylam Ranks 1 on Boston Globe's Top Places to Work List for 2022
AQ
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2022
BU
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Piper Sandler 34th Annual Healthcare Conference, Nov-30-2022 09:30 AM
Transcript : Alnylam Pharmaceuticals, Inc. Presents at 13th Annual Jefferies London Healthcare Conference 2022, Nov-16-2022 02:05 PM
Transcript : Alnylam Pharmaceuticals, Inc., Q3 2022 Earnings Call, Oct 27, 2022
Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity
BU
No results for this search
  1. Stock Market
  2. Advanced search
  3. Yvonne Greenstreet
  4. News